Flag of the European Union EU Clinical Trials Register Help

Clinical trials for bevacizumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    844 result(s) found for: bevacizumab. Displaying page 1 of 43.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005523-15 Sponsor Protocol Number: ulcn0107 Start Date*: 2008-07-17
    Sponsor Name:Radboud University Medical Centre
    Full Title: A phase II study of carboplatin –paclitaxel with bevacizumab followed by the addition of erlotinib to bevacizumab beyond progression in patients with locally advanced and/or metastatic non-small ce...
    Medical condition: advanced non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003669-87 Sponsor Protocol Number: M14-064 Start Date*: 2018-03-19
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 and FOLFIRI vs Bevacizumab and FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab
    Medical condition: metastatic adenocarcinoma of the colon or rectum previously treated with a regimen containing fluoropyrimidine/oxaliplatin and bevacizumab
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005887-97 Sponsor Protocol Number: MO19390 Start Date*: 2006-07-06
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label study of bevacizumab (AVASTIN®) in combination with platinum-containing chemotherapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer
    Medical condition: Advanced or recurrent non-squamous non-small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    9 10059515 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FI (Completed) SE (Completed) ES (Completed) NL (Completed) AT (Completed) CZ (Completed) EE (Completed) DE (Completed) LT (Completed) HU (Completed) SK (Completed) GB (Completed) PT (Completed) DK (Completed) LV (Completed) IS (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003170-99 Sponsor Protocol Number: IVB JSA Start Date*: 2007-07-24
    Sponsor Name:UNIVERSITA DEGLI STUDI DI UDINE
    Full Title: Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration
    Medical condition: Exudative age-related macular degeneration
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061763 Chorioretinal disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002009-31 Sponsor Protocol Number: MO25757 Start Date*: 2012-03-23
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A single arm open label multicentre extension study of bevacizumab in patients with solid tumours on study treatment with bevacizumab at the end of a F. Hoffmann-La Roche and/or Genentech sponsored...
    Medical condition: Solid tumours
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10049280 Solid tumour LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) ES (Completed) SK (Completed) NL (Completed) FR (Completed) IT (Prematurely Ended) DE (Completed) EE (Completed) HU (Completed) LV (Prematurely Ended) AT (Completed) GR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2007-006611-23 Sponsor Protocol Number: MO21609 Start Date*: 2008-10-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Open-label, single-arm, phase II study of bevacizumab (AVASTIN®) in combination with low-dose interferon as first-line treatment of nephrectomised patients with metastatic clear cell renal cell car...
    Medical condition: Metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050513 Metastatic renal cell carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) NL (Completed) PT (Completed) GB (Completed) FI (Completed) SE (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-001031-39 Sponsor Protocol Number: 69HCL17_0018 Start Date*: 2017-05-19
    Sponsor Name:Hospices Civils de Lyon
    Full Title: BABH Study: Efficacy and safety of bevacizumab on severe bleedings associated with Hemorrhagic Hereditary Telangiectasia (HHT). A National, randomized multicenter phase III study.
    Medical condition: Hemorrhagic Hereditary Telangiectasia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10031132 Osler-Weber-Rendu disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005175-78 Sponsor Protocol Number: SAMSON-II Start Date*: 2019-10-10
    Sponsor Name:Prestige BioPharma Limited
    Full Title: A Randomized, Double-blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metas...
    Medical condition: Non-squamous Non-small Cell Lung Cancer (nsNSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10079440 Non-squamous non-small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) GR (Completed) PL (Completed) BG (Completed) LV (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003878-16 Sponsor Protocol Number: B7391003 Start Date*: 2015-05-27
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A Phase 3 randomized, double-blind study of PF-06439535 plus Paclitaxel-Carboplatin and Bevacizumab plus Paclitaxel-Carboplatin for the first-line treatment of patients with advanced non-squamous n...
    Medical condition: Advanced non-squamous non-small cell lung cancer.
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) NL (Completed) CZ (Completed) DE (Completed) ES (Completed) PL (Completed) HU (Completed) GR (Completed) HR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006414-19 Sponsor Protocol Number: RD 2007-114 Start Date*: 2009-04-27
    Sponsor Name:East and North Hertfordhsire NHS Trust
    Full Title: Dynamic contrast enhanced MRI (DCE-MRI) assessment of the vascular changes induced with bevacizumab alone and in combination with interferon-α in patients with advanced renal cell carcinoma.
    Medical condition: Previously untreated metastatic (stage IV) or locally advanced (inoperable stage III), renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038408 Renal cell carcinomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002886-11 Sponsor Protocol Number: BEBYP Start Date*: 2008-01-14
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO NORD OVEST
    Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE III STUDY OF SECOND-LINE CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB IN METASTATIC COLORECTAL CANCER PATIENTS WHO HAVE RECEIVED FIRST-LINE CHEMOTHERAPY PLU...
    Medical condition: METASTATIC COLORECTAL CANCER PATIENTS
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002700-21 Sponsor Protocol Number: OOI/Onkocytogenetika/2022/01 Start Date*: 2023-02-28
    Sponsor Name:National Institute of Oncology [...]
    1. National Institute of Oncology
    2. National Institute of Oncology
    Full Title: An open label, Phase IV study to assess immunological changes in patients with glioblastoma multiforme treated with bevacizumab infusion
    Medical condition: Glioblastoma multiforme
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020998-16 Sponsor Protocol Number: MO22998 Start Date*: 2010-11-22
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: ESTUDIO FASE III RANDOMIZADO PARA EVALUAR LA EFICACIA Y SEGURIDAD DEL TRATAMIENTO CONTINUADO Y DE REINDUCCIÓN CON BEVACIZUMAB EN COMBINACIÓN CON QUIMIOTERAPIA EN PACIENTES CON CÁNCER DE MAMA LOCALM...
    Medical condition: Locally recurrent (LR) or metastatic breast cancer (mBC) progressing after first-line chemotherapy and bevacizumab treatment. Pacientes con cáncer de mama localmente recurrente (LR) o metastásico (...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SK (Completed) HU (Completed) AT (Completed) DE (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004269-26 Sponsor Protocol Number: ENGOT-ov24-NSGO Start Date*: 2015-05-22
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit
    Full Title: Niraparib versus niraparib-bevacizumab combination in Women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Part 1: AVANOVA1 - A phase I study to evaluate the saf...
    Medical condition: Women with relapsed platinum-sensitive epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DK (Completed) SE (Completed) NO (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2008-006265-93 Sponsor Protocol Number: AVO1 Start Date*: 2009-03-11
    Sponsor Name:St Eriks Eye Hospital
    Full Title: A prospective, randomized, masked and controlled trial of intravitreal bevacizumab (Avastin®) for central retinal vein occlusion (CRVO).
    Medical condition: Central retinal vein occlusion (CRVO) is a sight-threatening ocular condition without efficient treatment.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-003288-21 Sponsor Protocol Number: EURIVAT2 Start Date*: 2005-09-28
    Sponsor Name:Dept. of Ophthalmology, Medical University of Vienna
    Full Title: INTRAOCULAR BEVACIZUMAB (AVASTIN™) FOR CENTRAL AND BRANCH RETINAL VEIN OCCLUSION STUDY
    Medical condition: CENTRAL AND BRANCH RETINAL VEIN OCCLUSION
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010857-10 Sponsor Protocol Number: BEV-PROT-001 Start Date*: 2009-07-23
    Sponsor Name:Universitätsklinik für Kinder- und Jugendheilkunde, Medizinsiche Universität Wien
    Full Title: Proteinuria in patients with bevacizumab (Avastin®): Identification of potential protein biomarker candidates for monitoring treatment side-effects
    Medical condition: Recurrent malignant childhood central nervous system tumors
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006872-31 Sponsor Protocol Number: MO22223 Start Date*: 2009-05-20
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: Estudio fase III randomizado de bevacizumab más capecitabina versus bevacizumab solo, como tratamiento de mantenimiento en pacientes con cáncer de mama metastático HER2-negativo que no hayan progre...
    Medical condition: Tratamiento de pacientes con cáncer de mama metastático negativo para HER-2 que no han manifestado progresión durante el tratamiento de primera línea con docetaxel más bevacizumab. HER2-negative me...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055113 Breast cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Temporarily Halted) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-004974-27 Sponsor Protocol Number: BP28015 Start Date*: 2012-03-26
    Sponsor Name:University Medical Center Groningen
    Full Title: 89Zr-RO5323441 PET imaging in patients with recurrent glioblastoma treated with bevacizumab
    Medical condition: Recurrent malignant glioma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000156-35 Sponsor Protocol Number: NF2PET Start Date*: 2021-03-18
    Sponsor Name:Leiden University Medical Center
    Full Title: 89Zr-Bevacizumab PET/CT imaging of vestibular schwannomas for the prediction of bevacizumab treatment effect in patients with symptomatic neurofibromatosis type 2.
    Medical condition: Neurofibromatosis type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 07:49:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA